|Mr. William H. Lewis J.D.||Pres, CEO & Chairman||1.24M||N/A||1969|
|Ms. Christine A. Pellizzari J.D.||Chief Legal Officer & Corp. Sec.||730.61k||N/A||1968|
|Mr. Roger Adsett||Chief Commercial Officer||773.14k||N/A||1969|
|Dr. Paul D. Streck||Advisor||733.67k||N/A||1964|
|Mr. John Goll III||Chief Accounting Officer||N/A||N/A||N/A|
Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated’s ISS Governance QualityScore as of April 1, 2019 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 10; Compensation: 6.